论文部分内容阅读
SARS-CoV-2感染是对全世界人类生命和健康的一大严重威胁,新型冠状病毒肺炎是由SARS-CoV-2感染引起的全球流行病.SARS-CoV-2病毒具有高度的传染性、诡异性和多变性.因此,新型冠状病毒肺炎的治疗是紧迫且有针对性的.然而,疫苗和目前使用的药物一般不具有上述特点.虽然新型冠状病毒肺炎的恢复期血浆在危重患者的急诊治疗中己显示出临床应用价值,但仍具有很大的局限性.全人源重组多价中和纳米抗体可能满足新型冠状病毒肺炎治疗的不足.基因工程技术已被应用于开发特异性中和抗体(nAB)药物,用于治疗世界范围内的新型冠状病毒肺炎.一些候选的nAB药物已经进入临床试验,并且可以很快用于新型冠状病毒肺炎的治疗.在本综述中,我们从以下五个方面分析和研究nABs治疗新型冠状病毒肺炎的进展和前景:1)SARS-CoV-2感染的生物学和临床特点;2)新型冠状病毒肺炎康复者血浆治疗的可行性;3)开发nAB药物的技术路线;4)开发全球新型冠状病毒中和抗体的现状;5)困难和临床应用前景.“,”SARS-CoV-2 infection is a serious threat to human life and health all over the world,and COVID-19 is a global epidemic caused by SARS-CoV-2 infection.SARS-CoV-2 is highly infectious,strange and variable.Therefore,the treatment of COVID-19 must be urgent and targeted.However,vaccines and currently used drugs generally do not have the above-mentioned characteristics.Although convalescent plasma of COVID-19 has shown a clinical application value in the emergency treatment of critical patients,it shows great limitations.All human recombinant multivalent neutralizing nano-antibodies may meet the deficiency of COVID-19 therapy.Gene engineering technologies have been used to develop specific neutralizing antibody(nAB)drugs for the treatment of COVID-19 worldwide.Some of the candidate nAB drugs have been entered the clinical trials and can be used for the therapy of COVID-19 shortly.In the present review,we studied and analyzed nABs for the treatment of COVID-19 and the progress and prospect from the following five aspects:1)The biological and clinical characteristics of SARS-CoV-2 infection;2)The feasibility of plasma therapy for convalescents with COVID-19;3)The technical routes of developing nAb drugs;4)The current status of developing global COVID-19 antibodies;5)The difficulties and clinical use.